In a randomized clinical trial of a neoadjuvant vaccine for low-grade gliomas, investigators found that neoadjuvant vaccination induced the expansion of effector CD8+ T cells in peripheral blood and prompted vaccine-responsive migration of CD8+ T cells into the TME [276]. The gene discussed is CD8A; the disease is central nervous system cancer.